Eli Lilly and Company (NYSE:LLY) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 25.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,000 shares of the company’s stock after purchasing an additional 3,696 shares during the quarter. Eli Lilly and Company accounts for 1.1% of GAMMA Investing LLC’s investment portfolio, making the stock its 10th largest holding. GAMMA Investing LLC’s holdings in Eli Lilly and Company were worth $14,866,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Knightsbridge Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock valued at $628,000 after buying an additional 15 shares during the last quarter. LS Investment Advisors LLC lifted its position in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after acquiring an additional 40 shares in the last quarter. CSM Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock valued at $807,000 after purchasing an additional 245 shares in the last quarter. Proficio Capital Partners LLC boosted its position in shares of Eli Lilly and Company by 30.2% during the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock valued at $5,202,000 after buying an additional 1,562 shares during the last quarter. Finally, Prosperity Wealth Management Inc. boosted its position in shares of Eli Lilly and Company by 6.8% during the fourth quarter. Prosperity Wealth Management Inc. now owns 2,123 shares of the company’s stock valued at $1,639,000 after buying an additional 135 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $776.18 on Friday. The stock has a fifty day simple moving average of $780.19 and a two-hundred day simple moving average of $799.94. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market cap of $735.61 billion, a price-to-earnings ratio of 63.16, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.58 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Guggenheim restated a “buy” rating and set a $936.00 price target on shares of Eli Lilly and Company in a report on Friday, June 20th. Finally, HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.